J Autoimmun:皮肤CD4+Trm细胞区分急性皮肤红斑狼疮和局限性盘状红斑狼疮/亚急性皮肤红斑狼疮及其他皮肤病

2022-03-21 医路坦克 MedSci原创

本文分析和比较急性CLE、亚急性CLE和局限性盘状红斑狼疮皮损患者外周血中经SMART RNA测序(SMART-SEQ)鉴定的CD4+Trm细胞和黑色素瘤中缺失的AIM2细胞。

 

     皮肤红斑狼疮(CLE)是一种自身免疫性疾病,表现为局限性皮肤病或皮肤表现,出现在70%-80%的系统性红斑狼疮(SLE)患者。CLE特异性皮肤损害可细分为急性CLE(ALE)、亚急性CLE(SCLE)和慢性CLE(CCLE)。主要的CCLE变异型是慢性盘状红斑狼疮(CDLE),又可细分为局限性DLE(局限性DLE:影响头部和面部皮肤)或播散性DLE(播散性DLE:影响颈部上方和下方皮肤)。器官受累的发生率在不同亚型的CLE患者中不同。值得注意的是,ALE的全身受累发生率最高(90%),而局限性DLE造成的损害总是局限于皮肤。

     在系统性红斑狼疮患者中,皮肤表现的利妥昔单抗反应在不同的皮损类型中是不同的。具体地说,在ALE患者中,抗B细胞疗法可以改善皮肤病的状况,而SCLE和CCLE患者对B细胞耗尽的反应较差。令人惊讶的是,在几名患有或没有皮肤病的患者中观察到了SCLE和CCLE的出现,而其他器官系统同时对利妥昔单抗治疗反应良好。因此,ACLE可能与B细胞信号和异常的CD4+T滤泡辅助细胞有更强的相关性,这些细胞可以诱导各种自身抗体的产生。Abatacept抑制T细胞激活,对一些难治性SLE患者有益,但会加重难治性SLE患者的DLE病变。CLE皮肤病变中的Trm细胞可能为不同CLE亚型之间的免疫病理差异提供了解释。

     问题驻留记忆T(Trm)细胞由CD69和/或CD103的表达定义,永久驻留在皮肤中,并迅速触发同源病原体衍生的局部炎症反应。到目前为止,存在于不同组织中的记忆T细胞在保护或病理过程中显示出组织特异性。由于Trm细胞寿命长,对破坏因素具有抵抗力,并具有持续的促炎优势,不适当的Trm细胞激活可能会导致免疫病理和同一部位的疾病持续时间延长,为了完全缓解疾病,需要设计出完全沉默Trm细胞的最佳治疗方案。

      在这项研究中,我们使用Smart-Seq分析了NCS和ALE患者皮肤中CD4+Trm细胞的基因表达谱。此外,采用免疫组织化学方法检测了局限性DLE、SCLE、ALE等炎症性皮肤病皮损中CD4+Trm细胞的数量和分布。我们的数据显示,来自NCS和ALE患者的CD4+Trm细胞具有不同的转录特性。多色免疫组织化学显示,与NCS相比,局限性DLE和SCLE患者的CD4+Trm细胞数量增加,但Acle患者的CD4+Trm细胞数量没有增加。

     我们用Smart-Seq研究了ALE患者和正常对照(NCS)真皮中CD4+Trm细胞的差异。应用多色免疫组织化学方法检测134例临床患者,包括局限性DLE(n=19)、ALE(n=19)、SCLE(n=16)、银屑病(n=12)、酒渣鼻(n=17)、扁平苔藓(n=18)、环状肉芽肿(n=15)和NCS(n=18)皮肤中CD4+Trm细胞的AIM2水平。

     Smart-Seq检测显示AIM2在ALE皮损的皮肤CD4+Trm细胞中的表达高于NCS(倍数变化>10,调整后P<0.05)。AIM2在CD4+Trm细胞中的表达不受年龄和性别的影响。ALE患者外周血中AIM2的表达显著低于局限性DLE(179.41±160.98)和SCLE(63.43±62.27,P<0.0001)。在ALE与局限性DLE和SCLE的总体比较中,AIM2表达的受试者操作特征曲线在截断值为18.26时的敏感性为100.00%,特异性为82.86%。ALE与局限性DLE比较,敏感性为89.47%,特异性为100.00%(以12.26为界值)。ALE与SCLE比较,敏感性为100.00%,特异度为75.00%,界值为18.26。

表1 CLE、银屑病、酒渣鼻、扁平苔藓、环状肉芽肿和NCS患者的人口学特征。

图1. 来自ALE患者的皮肤CD4?Trm细胞与NCS相比显示出不同的转录组表达谱。(1)从ACLE和NCS患者的皮肤中分离出CD4+Trm细胞。(B)散点图,显示Acle CD4+Trm细胞(y轴)和正常CD4+Trm细胞(x轴)之间基因表达的差异。然后对这些值进行平均,以获得每个组的归一化信号值(按对数2标度)。(C)通过KEGG分析对差异表达基因(Deg)进行分类。(D)通过GO分析对差异表达基因(DEG)进行分类。

图2. 皮肤CD4+Trm细胞在NCS、ALE、SCLE和局限性DLE患者中的数量和分布。(A-D)免疫组织化学染色在NCS、ALE、SCLE和局限性DLE患者的石蜡切片中。CD4(绿色)、CD69(黄色)、CD103(白色)。(E)比较NCS(n=18)、局限性DLE(n=19)、Acle(n=19)和SCLE(n=16)患者的CD4+Trm细胞。(F)NCS(n=18)与局限性DLE(n=19)、Acle(n=19)和SCLE(n=16)患者的CD4+细胞比较。**P<0.001,*P<0.0001;Kruskal-Wallis检验和Dunn‘s多重后置检验。

图3.7例炎症性皮肤病患者皮肤中CD4+Trm细胞的数量和分布。(A)Acle、SCLE、局限性DLE、牛皮癣、酒渣鼻、扁平苔藓和环状肉芽肿患者石蜡切片中的多重免疫组织化学染色。CD4(绿色)、CD69(黄色)、CD103(白色)。(2)ALE患者(n=19)与银屑病(n=12)、酒渣鼻(n=17)、扁平苔藓(n=18)、环状肉芽肿(n=15)患者外周血中CD4+Trm细胞的比较。(C)系统性红斑狼疮患者(n=16)与银屑病患者(n=12)、酒渣鼻患者(n=17)、扁平苔藓患者(n=18)、环状肉芽肿患者(n=15)外周血中CD4+Trm细胞的比较。(D)局限性DLE患者(n=18)与银屑病患者(n=12)、酒渣鼻患者(n=17)、扁平苔藓患者(n=18)、环状肉芽肿患者(n=15)外周血中CD4+Trm细胞的比较。**P<0.001,*P<0.0001;Kruskal-Wallis检验和Dunn‘s多重后置检验。

图4. AIM2在NCS、ALE、SCLE、DLE患者外周血中的表达。(A-D)免疫组织化学染色在NCS、ALE、SCLE和局限性DLE患者的石蜡切片中。CD4(绿色)、CD69(黄色)、CD103(白色)、AIM2(红色)。(E)比较NCS(n=18)、局限性DLE(n=19)、Acle(n=19)和SCLE(n=16)患者外周血中CD4+Trm细胞AIM2总荧光强度(TFI)。(F)比较NCS(n=18)、局限性DLE(n=19)、Acle(n=19)和SCLE(n=16)患者的CD4+细胞AIM2 TFI。**P<0.001,*P<0.0001;Kruskal-Wallis检验和Dunn‘s多重后置检验。

图5. 7例炎症性皮肤病患者CD4+Trm细胞中AIM2的表达。(A)Acle、SCLE、局限性DLE、牛皮癣、酒渣鼻、扁平苔藓和环状肉芽肿患者石蜡切片中的多重免疫组织化学染色。CD4(绿色)、CD69(黄色)、CD103(白色)、AIM2(红色)。(B)ALE患者(n=19)与银屑病(n=12)、酒渣鼻(n=17)、扁平苔藓(n=18)、环状肉芽肿(n=15)患者外周血CD4+Trm细胞AIM2 TFI的比较。(C)SCLE患者(n=16)与银屑病患者(n=12)、酒渣鼻患者(n=17)、扁平苔藓患者(n=18)、环状肉芽肿患者(n=15)的CD4+Trm细胞AIM2 TFI的比较。(D)比较局限性DLE(n=19)、银屑病(n=12)、酒渣鼻(n=17)、扁平苔藓(n=18)和环状肉芽肿(n=15)患者外周血中CD4+Trm细胞的AIM2 TFI。**P<0.001,*P<0.0001;Kruskal-Wallis检验和Dunn‘s多重后置检验。

图6. 基于皮肤CD4+细胞的ROC曲线,CD4+细胞的AIM2 TFI,CD4+Trm细胞的AIM2 TFI和CD4+Trm细胞的AIM2 TFI。(A)ALE患者与NCS患者的ROC曲线比较。(B)ALE患者与局限性DLE和SCLE患者的ROC曲线比较。(C)ALE患者与SCLE患者的ROC曲线比较。(D)ALE患者与局限性DLE患者的ROC曲线比较。**P<0.001,*P<0.0001;

     与ALE相比,在SCLE和局限性DLE的皮损中,CD4+Trm细胞的数量增加,提示在SCLE和局限性DLE的持续性皮损中,CD4+Trm细胞可能起着更重要的作用。此外,AIM2在CD4+Trm细胞中的表达可将ALE患者与局限性DLE和SCLE患者区分开来。

文献来源: Zhao Z,  Zhu H,  Li Q,  Liao W,Skin CD4 Trm cells distinguish acute cutaneous lupus erythematosus from localized discoid lupus erythematosus/subacute cutaneous lupus erythematosus and other skin diseases.J Autoimmun 2022 Mar 09;128

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1826166, encodeId=01601826166c3, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 20 00:39:40 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864307, encodeId=c4f5186430e3a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Aug 30 06:39:40 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652608, encodeId=8d291652608ac, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Fri Aug 19 20:39:40 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924055, encodeId=de1019240552f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Jun 06 16:39:40 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204551, encodeId=29e11204551c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:58:14 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387513, encodeId=3f62138e51352, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436335, encodeId=0ee21436335ed, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1826166, encodeId=01601826166c3, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 20 00:39:40 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864307, encodeId=c4f5186430e3a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Aug 30 06:39:40 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652608, encodeId=8d291652608ac, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Fri Aug 19 20:39:40 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924055, encodeId=de1019240552f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Jun 06 16:39:40 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204551, encodeId=29e11204551c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:58:14 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387513, encodeId=3f62138e51352, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436335, encodeId=0ee21436335ed, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
    2022-08-30 qidongfanjian
  3. [GetPortalCommentsPageByObjectIdResponse(id=1826166, encodeId=01601826166c3, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 20 00:39:40 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864307, encodeId=c4f5186430e3a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Aug 30 06:39:40 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652608, encodeId=8d291652608ac, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Fri Aug 19 20:39:40 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924055, encodeId=de1019240552f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Jun 06 16:39:40 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204551, encodeId=29e11204551c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:58:14 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387513, encodeId=3f62138e51352, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436335, encodeId=0ee21436335ed, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
    2022-08-19 xuyu
  4. [GetPortalCommentsPageByObjectIdResponse(id=1826166, encodeId=01601826166c3, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 20 00:39:40 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864307, encodeId=c4f5186430e3a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Aug 30 06:39:40 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652608, encodeId=8d291652608ac, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Fri Aug 19 20:39:40 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924055, encodeId=de1019240552f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Jun 06 16:39:40 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204551, encodeId=29e11204551c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:58:14 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387513, encodeId=3f62138e51352, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436335, encodeId=0ee21436335ed, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1826166, encodeId=01601826166c3, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 20 00:39:40 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864307, encodeId=c4f5186430e3a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Aug 30 06:39:40 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652608, encodeId=8d291652608ac, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Fri Aug 19 20:39:40 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924055, encodeId=de1019240552f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Jun 06 16:39:40 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204551, encodeId=29e11204551c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:58:14 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387513, encodeId=3f62138e51352, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436335, encodeId=0ee21436335ed, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
    2022-03-21 ms3000000876072209

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1826166, encodeId=01601826166c3, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 20 00:39:40 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864307, encodeId=c4f5186430e3a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Aug 30 06:39:40 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652608, encodeId=8d291652608ac, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Fri Aug 19 20:39:40 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924055, encodeId=de1019240552f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Jun 06 16:39:40 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204551, encodeId=29e11204551c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:58:14 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387513, encodeId=3f62138e51352, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436335, encodeId=0ee21436335ed, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1826166, encodeId=01601826166c3, content=<a href='/topic/show?id=f6a6e206066' target=_blank style='color:#2F92EE;'>#皮肤病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72060, encryptionId=f6a6e206066, topicName=皮肤病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Jul 20 00:39:40 CST 2022, time=2022-07-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864307, encodeId=c4f5186430e3a, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Tue Aug 30 06:39:40 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1652608, encodeId=8d291652608ac, content=<a href='/topic/show?id=5082432634' target=_blank style='color:#2F92EE;'>#CD4+#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4326, encryptionId=5082432634, topicName=CD4+)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4c1624305102, createdName=xuyu, createdTime=Fri Aug 19 20:39:40 CST 2022, time=2022-08-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1924055, encodeId=de1019240552f, content=<a href='/topic/show?id=61d24e655df' target=_blank style='color:#2F92EE;'>#局限性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47655, encryptionId=61d24e655df, topicName=局限性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7eeb2500172, createdName=haouestc, createdTime=Mon Jun 06 16:39:40 CST 2022, time=2022-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1204551, encodeId=29e11204551c3, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=78216166207, createdName=ms3000000876072209, createdTime=Mon Mar 21 09:58:14 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1387513, encodeId=3f62138e51352, content=<a href='/topic/show?id=8a3a6814425' target=_blank style='color:#2F92EE;'>#狼疮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68144, encryptionId=8a3a6814425, topicName=狼疮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a6e2500005, createdName=sunrural_42825357, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1436335, encodeId=0ee21436335ed, content=<a href='/topic/show?id=22f8e71238d' target=_blank style='color:#2F92EE;'>#红斑#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77123, encryptionId=22f8e71238d, topicName=红斑)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Mon Mar 21 08:39:40 CST 2022, time=2022-03-21, status=1, ipAttribution=)]
    2022-03-21 zhouqu_8

相关资讯

JEADV:Suckinumab与Ixekizumab治疗脓疱型和红皮病型银屑病的临床比较

脓疱性银屑病(PP)和红皮病型银屑病(EP)代表着两种需要及时治疗的银屑病亚型,本文比较了Suckinumab和Ixekizumab在PP和EP患者中的安全性和有效性。

JEADV:Gottron丘疹和其他累及手背的炎症性皮肤病的皮肤镜检查

皮肌炎(DM)是一种结缔组织疾病,以多种皮肤症状为特征,包括Gottron丘疹,日光征,本文目的描述Gottron丘疹的皮肤镜检查结果,并与其他累及手背的皮肤病的皮肤镜检查结果进行比较。

J Am Acad Dermatol:外用JAK-STAT抑制剂Tofacitinib有效减少非特应性皮炎慢性瘙痒

Janus激酶抑制剂Tofacitinib目前被认为是治疗慢性和难治性瘙痒的良好候选者,我们量化外用tofacitinib治疗非AD相关的慢性顽固性瘙痒的有效性,并了解它对哪些特定皮肤病诊断最有效。

JEADV:分泌型白细胞蛋白酶抑制剂调节银屑病中神经反射介导的皮肤屏障功能

分泌性白细胞蛋白酶抑制因子(SLPI)是天然免疫和获得性免疫的重要调节因子,本文通过SLPI缺陷小鼠和咪喹莫特诱导的银屑病实验模型评估SLPI在银屑病中的作用。

JEADV:布达鲁(brodalumab)单抗治疗中重度斑块型银屑病的远期疗效和安全性

银屑病是一种慢性的、免疫调节的疾病,影响着全世界大约1.25亿人。本文评估接受Brodalab单抗治疗的中重度银屑病患者在120周内的疗效、有效率和安全结果。

Allergy:T细胞受体测序表明银屑病是是一种以皮肤为重点的过敏原驱动的疾病

特应性皮炎(AD)和银屑病一个特点是T细胞渗入皮肤。目前尚不清楚这些浸润性T细胞在多大程度上是抗原特异性皮肤归巢T细胞或非特异性异质性旁观者细胞。本文就此进行相关阐述。